NEXGEL, Inc. (NXGLW) stock

NXGLWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NXGL

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 6/3072% below fair value

$0.01+0.00 (0.00%)

Close on Oct 30, 2026Market cap $34.21MP/E –Yield –

Earnings

Nexgel's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 11, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$3.69M

+28.1% on a year earlier

EPS, Q2 FY2026

–

-$0.09 a year earlier

Latest guidance

Reaffirmed

Aug 12, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Nexgel's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 11, 2026Expected	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 17, 2026before the open	$3.69M	+28.1%	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 12, 2025before the open	$2.93M	-0.3%	-$0.08	Release
Q2 FY2025ended Jun 30, 2025	Aug 12, 2025after the close	$2.88M	+100.0%	-$0.09	Release
Q1 FY2025ended Mar 31, 2025	May 13, 2025after the close	$2.81M	+121.3%	-$0.09	Release
Q4 FY2024ended Dec 31, 2024	Mar 24, 2025after the close	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 14, 2024after the close	$2.94M	+145.0%	-$0.11	Release
Q2 FY2024ended Jun 30, 2024	Aug 14, 2024after the close	$1.44M	+23.1%	-$0.14	Release
Q1 FY2024ended Mar 31, 2024	May 13, 2024after the close	$1.27M	+104.8%	-$0.14	Release
Q4 FY2023ended Dec 31, 2023	Apr 1, 2024before the open	$1.10M	+109.9%	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 13, 2023after the close	$1.20M	+111.3%	-$0.10	Release
Q2 FY2023ended Jun 30, 2023	Aug 14, 2023after the close	$1.17M	+108.6%	-$0.13	Release
Q1 FY2023ended Mar 31, 2023	May 15, 2023after the close	$620.00K	+56.6%	-$0.15	Release
Q4 FY2022ended Dec 31, 2022	Mar 27, 2023after the close	$524.00K	-1.7%	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 8, 2022after the close	$568.00K	–	-$0.22	Release
Q2 FY2022ended Jun 30, 2022	Aug 10, 2022after the close	$561.00K	–	-$0.19	Release
Q1 FY2022ended Mar 31, 2022	May 12, 2022after the close	$396.00K	–	-$0.33	Release
Q4 FY2021ended Dec 31, 2021	Mar 21, 2022after the close	$533.00K	–	–	Release
Q2 FY2021ended Jun 30, 2021	Jul 22, 2021before the open	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Nexgel guided for has been reported

Guidance vs results

The last range Nexgel gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
Q3 FY2024	Revenue	$2.20M	$2.94M	Above range
Q2 FY2023	Revenue	$1.00M	$1.17M	Above range

Guidance history

Every forecast Nexgel put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 12, 2025	revenue	FY2025	$13.00M	Reaffirmed
May 13, 2025	revenue	FY2025	$13.00M	New
Mar 24, 2025	revenue	FY2025	$13.00M	Reaffirmed
Jan 22, 2025	revenue	Q4 FY2024	$3.00M	Raised
Jan 22, 2025	revenue	FY2024	$8.60M	New
Jan 22, 2025	revenue	FY2025	$13.00M	New
Aug 14, 2024	revenue guidance	Q3 FY2024	$2.20M	Reaffirmed
Aug 14, 2024	revenue guidance	Q4 FY2024	$2.60M	Reaffirmed
Jul 8, 2024	Revenue	Q3 FY2024	$2.20M	New
Jul 8, 2024	Revenue	Q4 FY2024	$2.60M	New
Apr 1, 2024	revenue	Q1 FY2023	$1.25M	New
May 15, 2023	revenue	Q2 FY2023	$1.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.